High need for intensive care in paediatric acute myeloid leukaemia: A population-based study.
AML
children
incidence
intensive care
Journal
Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
17
07
2022
received:
27
05
2022
accepted:
21
07
2022
pubmed:
24
7
2022
medline:
12
10
2022
entrez:
23
7
2022
Statut:
ppublish
Résumé
Risk of treatment-related life-threatening toxicity is high in childhood acute myeloid leukaemia (AML), and access to intensive care units (ICU) is crucial. We explored the ICU admission rate and outcome after intensive care in childhood AML in Sweden. Patients diagnosed between 2008 and 2016 were identified from the Swedish Childhood Cancer Registry (SCCR), a national quality registry. Data from SCCR was cross-referenced with clinical questionnaire data from paediatric oncology centers and the Swedish Intensive Care Registry (SIR), another national quality registry. According to combined data, 46% of the children (58/126) were admitted to ICU, 17% (21/126) within 1 month from diagnosis. Overall, ICU mortality per admission was 12% and 6% during first-line treatment. There was a discrepancy between admission rate from the clinical questionnaires and SCCR (29%; 36/126 children) and SIR (44%; 55/126) All deaths during first-line treatment occurred at or after ICU care. Although admission rate under AML treatment was high, the treatment-related mortality under first-line treatment was low. No child died under first-line treatment without admission to ICU, suggesting good availability. The discrepancy between the two registries, SCCR and SIR, highlights the need for future validation of registry data.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2235-2241Subventions
Organisme : Barncancerfonden
ID : TJ2019-0048
Organisme : Swedish Childhood Cancer Foundation
Informations de copyright
© 2022 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica.
Références
Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29(3):310-315.
Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving Progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33(27):2949-2962.
Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187-31205.
Reinhardt D, Antoniou E, Waack K. Pediatric acute myeloid leukemia-past, present, and future. J Clin Med. 2022;11(3):504.
Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid Leukaemia: medical research council AML12 trial. Br J Haematol. 2011;155(3):366-376.
Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's oncology group trial AAML0531. J Clin Oncol. 2014;32(27):3021-3032.
Lohmann DJ, Abrahamsson J, Ha SY, et al. Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004. Haematologica. 2016;101(11):1359-1367.
Dursun O, Hazar V, Karasu GT, Uygun V, Tosun O, Yesilipek A. Prognostic factors in pediatric cancer patients admitted to the pediatric intensive care unit. J Pediatr Hematol Oncol. 2009;31(7):481-484.
Zinter MS, DuBois SG, Spicer A, Matthay K, Sapru A. Pediatric cancer type predicts infection rate, need for critical care intervention, and mortality in the pediatric intensive care unit. Intensive Care Med. 2014;40(10):1536-1544.
Hasle H, Abrahamsson J, Forestier E, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood. 2012;120(5):978-984.
Lamble AJ, Tasian SK. Opportunities for immunotherapy in childhood acute myeloid leukemia. Blood Adv. 2019;3(22):3750-3758.
Ranta S, Broman LM, Abrahamsson J, et al. ICU admission in children with acute lymphoblastic leukemia in Sweden: prevalence, outcome, and risk factors. Pediatr Crit Care Med. 2021;22:1050-1060.
Lunkka P, Malila N, Ryynanen H, Heikkinen S, Sallinen V, Koskenvuo L. Accuracy of Finnish cancer registry colorectal cancer data: a comparison between registry data and clinical records. Scand J Gastroenterol. 2021;56(3):247-251.
Kao CW, Chiang CJ, Lin LJ, et al. Accuracy of long-form data in the Taiwan cancer registry. J Formos Med Assoc. 2021;120(11):2037-2041.
Foresto SA, Youlden DR, Baade PD, Hallahan AR, Aitken JF, Moore AS. The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: a report from the Australian Paediatric cancer registry. Pediatr Blood Cancer. 2015;62(9):1664-1666.
Maude SL, Fitzgerald JC, Fisher BT, et al. Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatr Crit Care Med. 2014;15(2):112-120.